Recent advances in tuberculosis treatment: Towards shorter, safer, and more effective therapies

TL;DR

This paper reviews recent progress in TB treatments, aiming to shorten treatment duration, reduce side effects, and improve effectiveness against drug-resistant strains.

Contribution

The paper summarizes recent clinical trials and WHO guidelines to highlight emerging therapies for various forms of TB.

Findings

New and repurposed drugs are being tested to shorten TB treatment regimens.

Emerging therapies show promise in improving safety and effectiveness for drug-resistant TB.

WHO guidelines are being updated to reflect advances in TB treatment strategies.

Abstract

Tuberculosis (TB), caused by Mycobacterium tuberculosis, is the leading infectious cause of death globally. Although effective treatments are available, treatment length, drug toxicity, and the emergence of drug-resistant strains have challenged TB control efforts. Current clinical trials are focused on developing shorter, safer, and more effective regimens that incorporate both new and repurposed agents for the treatment of TB. This narrative review provides an overview of current and emerging treatment options for drug-susceptible, drug-resistant, and latent TB based on recent clinical trials and WHO guidelines.